The DOI matches its Crossref record.
Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial
Abstract
In Brief Objective: The aim of this study was to assess the safety and efficacy of bazedoxifene (BZA)/conjugated estrogens (CE) treating moderate to severe vasomotor symptoms in the Selective Estrogen Menopause and Response to Therapy 2 trial. Methods: This was an outpatient, multicenter, double-blind, randomized, placebo-controlled, phase 3 study conducted in the United States. Healthy postmenopausal women (N = 332; aged 40-65 y) with moderate to severe hot flushes (≥7/d or 50/wk) were randomized to BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, or placebo once daily for 12 weeks. Changes from baseline in the average daily number of moderate and severe hot flushes and daily severity score were assessed at weeks 4 and 12; adverse events were recorded. Results: BZA/CE significantly reduced the number and severity of hot flushes at weeks 4 and 12 (P < 0.001). At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg reduced hot flushes from baseline by 74% (10.3 hot flushes [baseline] vs 2.8 [week 12]) and 80% (10.4 vs 2.4), respectively, compared with 51% (10.5 vs 5.4) for placebo. More participants at week 12 had at least a 75% decrease in hot flushes with BZA 20 mg/CE 0.45 mg (61%) and BZA 20 mg/CE 0.625 mg (73%) versus placebo (27%; P < 0.001). The safety profile was similar between BZA/CE and placebo, and no unexpected safety findings were reported. Conclusions: BZA 20 mg paired with CE 0.45 or 0.625 mg is effective, with short-term safety, for treating vasomotor symptoms in postmenopausal women. Postmenopausal women aged 40 to 65 years with 7 or more moderate to severe hot flashes per day or 50 per week enrolled in a 12-week placebo controlled, double-blind hot flash efficacy trial. Bazedoxifene 20 mg paired with conjugated estrogens 0.45 or 0.625 mg was found to be effective and safe in this trial for treating vasomotor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612
Management of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
de Villiers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., Davis, S. R., Gompel, A. A., Henderson, V. W., Langer, R., et al. (2013) · Climacteric · doi:10.3109/13697137.2013.795683 · Cited by 298
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Sakr, S., Naqvi, H., Komm, B., & Taylor, H. S. (2014) · Endocrinology · doi:10.1210/en.2013-1977 · Cited by 91
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women
Mirkin, S., Komm, B. S., Pan, K., & Chines, A. A. (2013) · Climacteric · doi:10.3109/13697137.2012.717994 · Cited by 83
Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention
Pinkerton, J. V., Pickar, J. H., Racketa, J., & Mirkin, S. (2012) · Climacteric · doi:10.3109/13697137.2012.696289 · Cited by 35
Self-citation
Metadata
- Authors
- Pinkerton, J. V., Utian, W. H., Constantine, G. D., Olivier, S., & Pickar, J. H.
- Venue
- Menopause
- Published
- 2009-11
- Volume
- 16
- Issue
- 6
- Pages
- 1116-1124
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2049340857
- Cited by
- 184
- References
- 0
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.